CLINICAL_TRIALS
trial_result
· 2010-01-13
Clinical Trial Update: Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine [Phase 1]
Summary
A Phase 1 trial evaluating safety and immune response of a two-dose regimen of the rDEN1delta30 dengue virus vaccine.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED